Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871441 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01871441 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 4 participants.
The verdict
NCT01871441, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant works in treating patients with hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. Giving an infusion of the donor's T cells (donor lymphocyte infusion) may replace the patient's immune cells and help destroy any remaining cancer cells. When the stem cells from a related donor, that closely matches the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- RADIATION Total-body irradiation
- PROCEDURE Allogeneic hematopoietic stem cell transplantation (HSCT)
- BIOLOGICAL Donor lymphocytes infusion (DLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-05-17 |
| Est. Completion | 2016-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01871441
The ClinicalTrials.gov registry entry for NCT01871441 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01871441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01871441 about?
NCT01871441 is a clinical study titled "Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies". This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant works in treating patients with hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patien...
What is the current status of trial NCT01871441?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2013-05-17. Estimated completion is 2016-10-20.
What interventions are being tested in trial NCT01871441?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Total-body irradiation (RADIATION), Allogeneic hematopoietic stem cell transplantation (HSCT) (PROCEDURE), Donor lymphocytes infusion (DLI) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01871441?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.